Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day. The stock lagged the S&P 500's daily gain of 1.68%. Meanwhile, the Dow gained 1.06%, and the Nasdaq, a tech-heavy index, lost 1.7%.

Prior to today's trading, shares of the company had lost 10.99% over the past month. This has lagged the Medical sector's loss of 5.62% and the S&P 500's loss of 6.68% in that time.

Wall Street will be looking for positivity from Biogen Inc. as it approaches its next earnings report date. In that report, analysts expect Biogen Inc. to post earnings of $3.34 per share. This would mark a year-over-year decline of 7.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.35 billion, down 7.13% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $15.47 per share and revenue of $9.58 billion, which would represent changes of -12.45% and -5.88%, respectively, from the prior year.

Any recent changes to analyst estimates for Biogen Inc. should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.54% lower. Biogen Inc. is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that Biogen Inc. has a Forward P/E ratio of 16.71 right now. This valuation marks a discount compared to its industry's average Forward P/E of 18.05.

Also, we should mention that BIIB has a PEG ratio of 2.19. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.54 based on yesterday's closing prices.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 99, which puts it in the top 40% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow BIIB in the coming trading sessions, be sure to utilize Zacks.com.

Free Report: Must-See Hydrogen Stocks

Hydrogen fuel cells are already used to provide efficient, ultra-clean energy to buses, ships and even hospitals. This technology is on the verge of a massive breakthrough, one that could make hydrogen a major source of America's power. It could even totally revolutionize the EV industry.

Zacks has released a special report revealing the 4 stocks experts believe will deliver the biggest gains.

Download Cashing In on Cleaner Energy today, absolutely free.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.